Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + lenvatinib in second-line advanced intrahepatic cholangiocarcinoma
ChiCTR2300078869Phase 2Recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Dec 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and lenvatinib in intrahepatic cholangiocarcinoma (ICC) and cholangiocarcinoma (CCA), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoints: overall survival and time to progression. Started Dec 2023; status: recruiting.
02
Drugs
adebrelimablenvatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2300078869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078869.